Oryzon Genomics S.A. (ORYZF) Comparison with companies in other sectors?

Oryzon Genomics S.A. has a share price of 77.51M. You can analyze Oryzon Genomics S.A. (ORYZF) competitors across different market sectors through stock heatmaps.

What are ORYZF's NET and operating margins?

Oryzon Genomics S.A. (ORYZF) operating margin is around 0.07, and net profit margin is approximately -1.00 as of the latest reports.

In what way does ORYZF's earnings per share (EPS) trend reflect its financial momentum?

Oryzon Genomics S.A. (ORYZF) EPS is -0.07 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Oryzon Genomics S.A. is -46.86, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Oryzon Genomics S.A.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Oryzon Genomics S.A. like P/E which is -44.20, P/B which is 2.08, and PEG which is 2.58. Compare them with sector averages to evaluate if the stock is priced fairly.

Oryzon Genomics S.A.

ORYZF•PNK

Healthcare

Biotechnology

$3.28

$-0.00(-0.08%)

Fundamental Analysis of Oryzon Genomics S.A. (ORYZF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.07

P/E Ratio

-46.86

ROE

-0.05%

Net Margin

-1.00%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$254.24M

Shares OutstandingTotal number of shares issued

$77.51M

Book Value/ShareNet worth per share

$1.34

Revenue/ShareAnnual revenue per share

$0.06

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.07

Net MarginNet income as percentage of revenue

-99.60%

Operating MarginOperating income as percentage of revenue

6.70%

ROEReturn on shareholders' equity

-4.71%

ROAReturn on total assets

-3.76%

ROCEReturn on capital employed

0.28%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$0.09

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ORYZFFinancial Ratios Analysis details for ORYZF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ORYZFSector Benchmarking details for ORYZF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Oryzon Genomics S.A. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Oryzon Genomics S.A.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Oryzon Genomics S.A.'s unique business strengths and challenges.

Key Financial Metrics for Oryzon Genomics S.A.

For Oryzon Genomics S.A., essential financial indicators include EPS -0.07, PE -46.86, and ROE -0.05. These key ratios reveal insights into Oryzon Genomics S.A.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Oryzon Genomics S.A. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Oryzon Genomics S.A.

Metrics like Net Margin -99.60% and ROA -3.76% shed light on how well Oryzon Genomics S.A. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Oryzon Genomics S.A. can sustain its operations and continue growing in the future.

Valuation and Market Position of Oryzon Genomics S.A.

Using ratios such as P/B Ratio 2.08 and PEG Ratio 2.58, investors can assess whether Oryzon Genomics S.A. is appropriately valued based on its financials and growth potential. These figures, combined with Oryzon Genomics S.A.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Oryzon Genomics S.A.

Financial health indicators, such as Debt/Equity Ratio 0.13 and Cash Flow -, provide a snapshot of Oryzon Genomics S.A.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Oryzon Genomics S.A., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Oryzon Genomics S.A.

Investing in Oryzon Genomics S.A. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Oryzon Genomics S.A. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;